Contact Us
Drug Search Results
More Filters [+]

Lorvotuzumab mertansine

Alternative Names: lorvotuzumab mertansine, bb-10901, imgn901
Latest Update: 2023-09-13
Latest Update Note: News Article

Product Description

Mechanisms of Action: CD56 Binder

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Lorvotuzumab mertansine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Small Cell Lung Cancer|Pulmonary Blastoma|Synovial Sarcoma|Wilms Tumor|Neuroblastoma|Rhabdomyosarcoma|Neurofibrosarcoma|Leukemia

Phase 1: Ovarian Cancer|Multiple Myeloma|Small Cell Lung Cancer|Carcinoma, Merkel Cell

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
ADVL1522

P2

Completed

Wilms Tumor|Neurofibrosarcoma|Pulmonary Blastoma|Synovial Sarcoma|Rhabdomyosarcoma|Neuroblastoma

2017-06-30

NCI-2015-00683

P2

Completed

Leukemia

2017-06-06

2010-022950-17

P2

Completed

Small Cell Lung Cancer

2015-05-12

Immunogen 0007

P2

Terminated

Small Cell Lung Cancer

2015-05-01

Recent News Events

Date

Type

Title

09/13/2023

News Article

 NK Cells market size is expected to expand at a 11.7% CAGR forecasted from 2023 - 2030

09/13/2023

News Article

 The K Cells market study's evaluation of the 5.3% CAGR forecasted for the K Cells industry from 2023 to 2030 helps identify growth opportunities and challenges.

01/01/2022

PubMed

 Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer.

12/15/2020

PubMed

 ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions